2022
Performance of plasma amyloid, tau, and astrocyte biomarkers to identify cerebral AD pathophysiology
Authors:
Ferreira, P.C.L., Tissot, C., Ferrari-Souza, J.P., Brum, W.S., Bellaver, B., Leffa, D.T., Therriault, J., Benedet, A.L., Lussier, F.Z., Chamoun, M., Bezgin, G., Servaes, S., Stevenson, J., Rahmouni, N., Pallen, V.**, Kang, M.S., Poltronetti, N.M., Tudorascu, D.L., Klunk, W.E., Villemagne, V.L., Cohen, A., Gauthier, S.*, Zimmer, E.R., Ashton, N.J., Zetterberg, H., Blennow, K., Karikari, T.K., Rosa-Neto, P.*, Pascoal, T.A.
Journal:
MedRxiv
Abstract
Introduction Plasma amyloid-β (Aβ), phosphorylated tau (p-tau), and glial fibrillar acid protein (GFAP) can identify Alzheimer’s disease (AD) pathophysiology with high accuracy. However, comparing their performance in the same individuals remains under-explored.
Methods We compared the predictive performance of plasma Aβ42/40, p-tau(at threonine 181 and 231), neurofilament light (NfL), and GFAP to identify Aβ- and tau-PET positivity in 138 cognitive unimpaired (CU) and 87 cognitive impaired (CI) individuals.
Results In CU, plasma p-tau231 had the best performance to identify both Aβ- and tau-PET positivity. In CI, plasma GFAP showed the best predictive accuracy to identify both Aβ and tau-PET positivity.
Discussion Our results support plasma p-tau231 as a marker of early AD pathology and, that GFAP best identifies both PET Aβ and tau abnormalities in the brain of CI individuals. These findings highlight that the performance of blood-based protein biomarkers to identify the presence of AD pathophysiology is disease-stage dependent.
Share
Receive the
latest news
Stay updated with the latest research developments from CCNA-CCNV. Our news section provides insights into cutting-edge studies, advancements in dementia care, and key findings in brain health research.
